Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 14/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859464 | 0.92 | OPRL1 (0.86) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL1865303 | 0.89 | OPRL1 (0.79) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1863856 | 0.87 | OPRM1 (0.76) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL13869097 | 0.85 | OPRL1 (0.73) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL1860312 | 0.85 | OPRM1 (0.74) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL14543172 | 0.83 | OPRM1 (0.71) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL7447387 | 0.82 | OPRL1 (0.69) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3871435 | 0.81 | OPRL1 (0.68) | OPRM1OPRL1OPRK1 | |
| SCHEMBL2554375 | 0.81 | OPRM1 (0.69) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1861481 | 0.80 | OPRM1 (0.67) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4455145-A2 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | Astraea Therapeutics, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | ASTRAEA THERAPEUTICS, LLC | 2024-02-22 | — | — | US | disclosed |
| US-RE49825-E1 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210053937-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2021-02-25 | — | — | US | disclosed |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC | 2020-11-10 | — | — | US | disclosed |
| US-20190300500-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | ASTRAEA THERAPEUTICS, LLC | 2019-10-03 | — | — | US | disclosed |
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
| EP-1598338-B1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1379246-B1 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2008-10-08 | — | — | EP | disclosed |
| EP-1930322-A1 | 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-06-11 | — | — | EP | disclosed |
| EP-1918279-A2 | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-05-07 | — | — | EP | disclosed |
| EP-0714299-B1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-04-24 | — | — | EP | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-10829471-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20210053937-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20190300500-A1 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.